OrthoPediatrics (KIDS) announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis, EOS. This represents the company’s 80th system designed to treat musculoskeletal issues in children.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics: Strategic Niche and Growth Potential Justify Buy Rating
- OrthoPediatrics initiated with a Buy at Lake Street
- OrthoPediatrics: Strong Market Position and Growth Potential Justify Buy Rating with $50 Price Target
- Orthopediatrics Corp Faces Financial Uncertainty Amidst Trade and Regulatory Challenges
- OrthoPediatrics Corp’s Earnings Call Highlights Growth and Record Impact